Trial Profile
RDD1609 as a Treatment for Idiopathic Pruritus Ani: A Randomized Double Blinded Placebo Controlled Crossover Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs RDD 1609 (Primary) ; Mebendazole
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors 9 Meters Biopharma [CEASED]; RDD Pharma
- 31 Oct 2022 Status changed from not yet recruiting to withdrawn prior to enrolment due to Covid-19 .
- 09 Mar 2020 Planned initiation date changed from 1 Feb 2020 to 1 May 2020.
- 25 Nov 2019 Planned initiation date changed from 1 Nov 2019 to 1 Feb 2020.